Revvity (RVTY) Set to Post Quarterly Earnings on Tuesday

Revvity (NYSE:RVTY) is expected to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of $1.30 per share and revenue of $694.73 million for the quarter. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 7:30 AM ET.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. The firm had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The business’s revenue was down 1.3% on a year-over-year basis. During the same period last year, the firm posted $1.18 EPS. On average, analysts expect Revvity to post $5.36 EPS for the current fiscal year and $5.92 EPS for the next fiscal year.

Revvity Stock Down 5.3%

NYSE RVTY opened at $156.95 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity has a 52 week low of $81.22 and a 52 week high of $169.06. The stock has a market capitalization of $17.51 billion, a P/E ratio of 74.74, a price-to-earnings-growth ratio of 2.86 and a beta of 1.06. The stock has a fifty day moving average of $144.54 and a 200-day moving average of $112.15.

Insider Buying and Selling

In other news, insider Tajinder S. Vohra sold 7,330 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares in the company, valued at $934,738.80. The trade was a 52.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the sale, the insider owned 14,781 shares of the company’s stock, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 9,045 shares of company stock valued at $1,281,439. Insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

RVTY has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Royal Bank Of Canada began coverage on Revvity in a report on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 price target on the stock. UBS Group assumed coverage on Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price objective for the company. William Blair assumed coverage on Revvity in a report on Monday, October 5th. They set an “outperform” rating for the company. Finally, KeyCorp lifted their target price on Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Five analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $124.43.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.